These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 26430825

  • 1. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
    Brigg Turner R, Elbarbry F, Biondo L.
    J Chemother; 2016 Aug; 28(4):304-7. PubMed ID: 26430825
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
    Lam W, Tjon J, Seto W, Dekker A, Wong C, Atenafu E, Bitnun A, Waters V, Yau Y, Solomon M, Ratjen F.
    J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
    Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ.
    Antimicrob Agents Chemother; 2000 Apr; 44(4):809-13. PubMed ID: 10722474
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    van Koningsbruggen-Rietschel S, Heuer HE, Merkel N, Posselt HG, Staab D, Sieder C, Ziegler J, Krippner F, Rietschel E.
    J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
    Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, Onishko CR, Martin AJ, Linke RJ, Holmes M, Jarvinen A, Kennedy D, Colebatch KA, Hansman D, Parsons DW.
    Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis.
    Sherwin CM, Zobell JT, Stockmann C, McCrory BE, Wisdom M, Young DC, Olson J, Ampofo K, Spigarelli MG.
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):71-9. PubMed ID: 24395072
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J.
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [Abstract] [Full Text] [Related]

  • 13. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Vandenbussche HL, Klepser ME.
    Lancet; 2007 Apr; 365(9459):547-8. PubMed ID: 15708080
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J, Cranswick N.
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [Abstract] [Full Text] [Related]

  • 15. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
    Adeboyeku D, Jones AL, Hodson ME.
    J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation.
    Peris-Marti JF, Borras-Blasco J, Rosique-Robles JD, Gonzalez-Delgado M.
    J Clin Pharm Ther; 2004 Feb; 29(1):65-70. PubMed ID: 14748900
    [Abstract] [Full Text] [Related]

  • 19. Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?
    Bos AC, Mouton JW, van Westreenen M, Andrinopoulou ER, Janssens HM, Tiddens HAWM.
    J Antimicrob Chemother; 2017 Dec 01; 72(12):3435-3442. PubMed ID: 29029057
    [Abstract] [Full Text] [Related]

  • 20. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A, TOPIC Study Group.
    Lancet; 2017 Dec 01; 365(9459):573-8. PubMed ID: 15708100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.